Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Session Type:

Participation Type:

HIVR4P Home

Funding for this conference was made possible in part by 1R13AI136762-01 from the National Institute of Allergy and Infectious Diseases. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices or organizations imply endorsement by the U.S. Government.

The conference was supported by Gilead, which provided funding. Gilead has had no input into the content of the materials used at this meeting/conference.

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 sessions: 1 to 13 of 13 from HIV Research for Prevention 2018
Plenary 03: The Future is Now: Next Steps in Developing New Prevention Options
Beyond TDF/FTC: The Future of Systemic Pre-exposure Prophylaxis
Raphael Landovitz
UCLA Center for Clinical AIDS Research & Education, United States
On-demand Topical Agents for HIV Pre-exposure Prophylaxis
Craig Hendrix
Johns Hopkins University, United States
Vaccine Design 2.0: The Pipeline Novel HIV-1 Envelope Proteins to Induce Neutralizing Antibodies
Rogier Sanders
Amsterdam University Medical Centers (Amsterdam UMC), University of Amsterdam, Netherlands
from HIV Research for Prevention 2018 on 24 October 2018 08:30-10:00
Oral Abstract Session 09: Translating Immunity From Pre-clinical Animal Models to Humans
Co-crystal Structure of SIVmac239 gp120 with rhCD4 and Neutralizing Antibody ITS90.03 Reveals Similar Sites of Vulnerability Between HIV-1 and SIV Env
Jason Gorman
NIH/NIAID/VRC, United States
Native HIV-1 Env Circulating During the Development of Breadth in Human Subjects Elicits Tier 2 Heterologous Neutralizing Monoclonal Antibodies in NHP
Ann Hessell
Oregon Health and Science University, United States
Macaque SHIV Induction of 2G12-like Broadly Neutralizing Antibodies
Wilton Bryan Williams
Duke University, United States
Tight Control of SHIV BaL.P4 Challenge in Rhesus Macaques Co-immunized With DNA and Protein HIV Vaccine Regimen
Miroslaw K. Gorny
New York University School of Medicine, Department of Pathology, United States
Tracking Cy5-conjugated VRC01 Following IV Injection in the Rhesus Macaque Reveals That Tissue Distribution Can Take 1 Week to Achieve Steady State
Jeffrey Schneider
Northwestern University, United States
A Meta-analysis to Evaluate the Relationship Between Serum Antibody Neutralizing Titer and Protection Against SHIV Challenge in Nonhuman Primates
Ying Huang
Fred Hutchinson Cancer Research Center, United States
from HIV Research for Prevention 2018 on 24 October 2018 10:30-12:00
Oral Abstract Session 10: Key to the Response: Populations, Partners and Prevention
Male Partners of Adolescent Girls and Young Women (AGYW) in Durban, South Africa: How High Is Their HIV Risk and What Groups Are Most at Risk?
Ann Gottert
Population Council, United States
Help-seeking Behavior of Women Reporting Intimate Partner Violence in Mwanza, Tanzania, and Its Implications for HIV: Findings From the MAISHA Study
Sheila Harvey
London School of Hygiene & Tropical Medicine, United Kingdom
Undercurrents of Sex Work: Characteristics and Experiences of Female Sex Workers in Kisumu, Kenya
Kawango Agot
Impact Research & Development Organization, Kenya
HIV Incidence Among Men Who Have Sex With Men and Transgender Women in Sub-Saharan Africa: Findings From the Multi-country HPTN 075 Cohort Study
Theo G.M. Sandfort
New York State Psychiatric Institute, United States
Young Transwomen in Brazil Have High HIV Risk and Low Prevention Use
Erin C Wilson
San Francisco Department of Public Health, United States
An Integrated Intervention to Increase ART and MAT Reduces Mortality Among PWID: Results From the HPTN 074 Randomized Trial
Kostyantyn Dumchev
Ukrainian Institute on Public Health Policy, Ukraine
from HIV Research for Prevention 2018 on 24 October 2018 10:30-12:00
Oral Abstract Session 11: Novel Vaccine Strategies
Combined Skin and Muscle DNA Priming Provides Enhanced Humoral Responses to an HIV-1 Clade C Envelope Vaccine
Robin Shattock
Imperial College, United Kingdom
Fusion Peptide-directed Antibodies Elicited in Immunized Rhesus Macaques Neutralized 59% of 208 Wildtype HIV-1 Strains
Rui Kong
Vaccine Research Center, NIAID, NIH, United States
Vaccination of Rabbits and Macaques With V1V2-scaffold Immunogens Induces V1V2-specific Antibody Responses With Antiviral Functions
Svenja Weiss
Icahn School of Medicine at Mount Sinai, United States
Immune Control of SHIV Infection in Rhesus Macaques by PD-1-based Vaccine
Yik Chun Wong
AIDS Institute, The University of Hong Kong, Hong Kong
Vaccine-elicited Cross-neutralizing HIV Antibodies (bNAbs) to Two Env Sites of Vulnerability Following Heterologous NFL Trimer Liposome Prime: Boosting
Richard Wyatt
IAVI Neutralizing Antibody Center at Scripps, United States
Immune Responses to PENNVAX-GP (R) HIV DNA Vaccine Plus IL-12 Are Equivalent or Superior When Delivered by Intradermal vs. Intramuscular Electroporation
Srilatha Edupuganti
Emory University, United States
from HIV Research for Prevention 2018 on 24 October 2018 10:30-12:00
Symposium 11: ARVs for Prevention in Women of Childbearing Age
No Woman Left Behind: An Ethical Framework for Prevention Studies in Reproductive Age Women
Annie Lyerly
University of North Carolina, United States
Efavirenz and Dolutegravir: A Tale of Two ARVs
Elaine Abrams
Columbia University, United States
Studying Periconception Outcomes in Women on ARVs in Brazil
Adele Benzaken
Ministry of Health, Brazil, Brazil
Striking a Balance
Sharon Hillier
University of Pittsburgh, United States
from HIV Research for Prevention 2018 on 24 October 2018 10:30-12:00
Oral Abstract Session 12: Contraception and HIV Risk: Still Between a Rock and a Hard Place
MPA, Used in Injectable Contraception, Increases HIV-1 Replication ex vivo by a Different Mechanism Compared to Luteal Phase Progesterone Levels
Chanel Avenant
University of Cape Town, South Africa
Safety and Pharmacokinetics of Dapivirine and Levonorgestrel Vaginal Rings for Multipurpose Prevention of HIV and Pregnancy
Sharon Achilles
University of Pittsburgh, United States
Increased CCR5 Levels Result in Increased R5-HIV Replication by Medroxyprogesterone Acetate, Unlike Norethisterone, via the Glucocorticoid Receptor
Janet Hapgood
University of Cape Town, South Africa
Effect of Depot-medroxyprogesterone Acetate on T Cell Expression of Immunosuppressive Markers, PD-1 and CTLA-4 in HIV-negative Women
Taguma A Matubu
University of Zimbabwe College of Health Sciences Clinical Trials Research Centre, Zimbabwe
Successful Use of Safer Conception Strategies Resulting in High Pregnancy Rates and no HIV Transmissions Among Kenyan HIV-discordant Couples
Renee Heffron
University of Washington, United States
Risk of HIV-1 Acquisition Among South African Women Using a Variety of Contraceptive Methods in a Prospective Study
Thesla Palanee-Phillips
Wits Reproductive Health and HIV Institute, South Africa
from HIV Research for Prevention 2018 on 24 October 2018 13:00-14:30
Oral Abstract Session 13: Virus Control: Therapeutic Interventions
Setting the Stage for Meaningful Community Engagement and Participation in HIV Cure-related Research: Lessons Learned From the HIV Prevention Field
Melissa Hermerding
Forum for Collaborative Research, University of California, Berkeley, School of Public Health, United States
A Novel Approach to Inhibit CD4 Exhaustion: Results of a Placebo-controlled Phase II Study of a gp41 Peptide Vaccine in HIV-1 Patients Under ART
Behazine Combabière
CIMI-Paris, France
DNA-GTU/LIPO-5 Vaccine Followed by Supervised Treatment Interruption (STI) in a Therapeutic HIV Phase II Randomized Trial: VRI02 ANRS 149 LIGHT
Christine Lacabaratz
Vaccine Research Institute/VRI, France
Therapeutic Vaccination With a Combination of IDLV-SIV-Gag and IDLV-PGT121 Results in Prolonged Virus Control in Chronically SHIV-infected Macaques
Maria Blasi
Duke University Medical Center, United States
Long-term Delivery of Anti-HIV Monoclonal Antibodies
Jose M. Martinez-Navio
University of Miami - Miller School of Medicine, United States
Tissue Viral Seeding Drives SHIV Pathogenesis in Infant Macaques and Is Reduced by Early bNAb Therapy
Ann Hessell
Oregon Health and Science University, United States
from HIV Research for Prevention 2018 on 24 October 2018 13:00-14:30
Oral Abstract Session 14: Antibody Functions Beyond Neutralization
HIV gp120 V2 Mimics IgSF Domain 1 of MAdCAM, the Natural Ligand of Integrin a4ß7
James Arthos
NIAID, NIH, United States
IgG3 Hinge Length Enhances Neutralization Potency and Fc Effector Function of an HIV V2-specific Broadly Neutralizing Antibody
Simone Irene Richardson
Centre for HIV & STIs, National Institute for Communicable Diseases, South Africa
Neutralizing and ADCC Activity of Anti-HIV-1 Antibodies Against Acute Subtype C Envs: Implications for Prevention and Treatment of HIV-1 Infection
Dieter Mielke
Duke University, United States
Structural Characterization of Rhesus Macaque Fc Domains of IgG1-4 and the FcγRIIIa1-IgG1Fc Complex
William Tolbert
Institute of Human Virology, University of Maryland, School of Medicine, United States
IgA Inhibits HIV-specific Antibody-dependent Neutrophil Phagocytosis
Matthew Worley
The Peter Doherty Institute for Infection and Immunity, University of Melbourne and Royal Melbourne Hospital, Australia
Tight Control of SHIVBaL in Rhesus Macaques Immunized With gp160 DNA + gp120 Proteins (Clades E and B) Correlates With V2p Antibodies
Svenja Weiss
Icahn School of Medicine at Mount Sinai, United States
from HIV Research for Prevention 2018 on 24 October 2018 13:00-14:30
Oral Abstract Session 15: New ARVs for Prevention
Pharmacokinetic and Pharmacodynamic Evaluation of the Antiretroviral Compound MK-2048 Released From an Intravaginal Ring in Rhesus Macaques
James Cummins
Division of AIDS, NIAID, NIH, United States
Efficacy of UAMC01398 Gel Formulation in NHP Model of HIV Vaginal Transmission
Delphine Desjardins
CEA Université Paris Sud, Inserm u1184, IDMIT Department, France
Dose-ranging Pharmacokinetic Assessment of Vaginally Administered EVG/TAF Inserts in Macaques for PrEP
Charles Dobard
Centers for Disease Control and Prevention, Division of HIV/AIDS Prevention, Laboratory Branch, United States
HIV Prevention in Healthy Women: Safety and Pharmacokinetics of a Potential New Tenofovir Alafenamide Fumarate (TAF)-based Oral PrEP Regimen
Jill Schwartz
CONRAD Eastern Virginia Medical School, United States
Cabotegravir (CAB) Long-acting (LA) Phase 3 (Ph3) PrEP Dose Selection Based on Population Pharmacokinetics (PPK) in Healthy and HIV-infected Adults
Susan Ford
PAREXEL International, United States
Tail-phase Safety, Tolerability and Pharmacokinetics of Long-acting Injectable Cabotegravir in HIV-uninfected Individuals: HPTN 077 Final Results
Raphael Landovitz
UCLA Center for Clinical AIDS Research & Education, United States
from HIV Research for Prevention 2018 on 24 October 2018 13:00-14:30
Round Table 01: Accelerating Product Introduction for Impact
Preparing for Successful Implementation of Prevention Strategies
Hasina Subedar
Department of Health, South Africa
Learning From the Past: Planning for Future Success in Implementing Biomedical HIV Prevention Products
Alex Coutinho
Partners in Health, Rwanda
Successes and Shortcomings in Introducing Sexual and Reproductive Health Technologies: Insights From End-users, Providers and Policy Makers
Martha Brady
PATH, United States
Learning from History: Roll-out of Non-HIV Vaccines
Swati Gupta
International AIDS Vaccine Initiative, United States
Introduction of New Health Technologies in HIV Prevention and Treatment Trials: Best Practices of Community Engagements and Communication in Peru
Maria del Rosario Leon
Impacta Salud y Educacion, Peru
Questions
Hasina Subedar
Department of Health, South Africa
Alex Coutinho
Partners in Health, Rwanda
Martha Brady
PATH, United States
Swati Gupta
International AIDS Vaccine Initiative, United States
Maria del Rosario Leon
Impacta Salud y Educacion, Peru
from HIV Research for Prevention 2018 on 24 October 2018 15:00-16:30
Symposium 05: Close Encounters of the Third Kind: Innate and Adaptive Immune Responses in HIV Dissemination
Interfering with Interferons: How HIV Subverts the Interferon System to Facilitate Sexual HIV Transmission
Anthony Cunningham
The Westmead Institute, The University of Sydney, Australia
Fixed Characteristics of HLA Class I Alleles That Impact HIV Disease
Mary Carrington
Frederick National Laboratory for Cancer Research, United States
HIV Persistence and the Immune Microenvironment in Lymph Nodes Following Initiation of cART During Hyperacute HIV-1 Infection
Zaza Ndhlovu
University of KwaZulu Natal, South Africa
The First Line Against HIV/SIV: Innate Immune Effectors at the Virus-Mucosae Interface
R. Keith Reeves
Beth Israel Harvard, United States
from HIV Research for Prevention 2018 on 24 October 2018 15:00-16:30
Symposium 06: Let's Talk T Cells!
T Cell Responses in HIV-infected Children: Potential for Prevention or Cure?
Maximilian Muenchhoff
Pettenkofer-Institute, Germany
T Cells in Vaccine Trials
Wendy Burgers
Institute of Infectious Disease and Molecular Medicine, UCT, South Africa
What Defines an Effective T-cell Response to HIV?
Christian Brander
IrsiCaixa, Spain
Role of Tfh in Protective Immunity
Tony Kelleher
Kirby Institute, UNSW Sydney, Australia
Vaccine-induced Th1-biased CD4 T Cell Responses: Too Much can be Bad
Rama Amara
Emory University, United States
from HIV Research for Prevention 2018 on 24 October 2018 15:00-16:30
Symposium 07: Optimizing PrEP Delivery for PrEP Users
Integrating PrEP and Reproductive Health Services and Preparing for MPT Delivery
Renee Heffron
University of Washington, United States
New Delivery Approaches: Improving PrEP Uptake and Persistence
Nneka Nwokolo
Chelsea & Westminster Hospital, United Kingdom
PrEP Messaging: Taking “Risk” Out of the Pitch
Sarit Golub
Hunter College, United States
Mobilizing Communities Through Innovations to Improve PrEP Uptake
Nittaya Phanuphak
Thai Red Cross AIDS Research Centre, Thailand
from HIV Research for Prevention 2018 on 24 October 2018 15:00-16:30
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 sessions: 1 to 13 of 13 from HIV Research for Prevention 2018